Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Non-Current Deffered Revenue (2016 - 2017)

Crescent Biopharma (CBIO) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $801058.0 as the latest value for Q3 2017.

  • On a quarterly basis, Non-Current Deffered Revenue fell 4.8% to $801058.0 in Q3 2017 year-over-year; TTM through Sep 2017 was $801058.0, a 4.8% decrease, with the full-year FY2016 number at $753579.0, up 209.29% from a year prior.
  • Non-Current Deffered Revenue was $801058.0 for Q3 2017 at Crescent Biopharma, down from $813182.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $880876.0 in Q2 2016 to a low of $9709.0 in Q3 2014.
  • A 5-year average of $390849.7 and a median of $243647.0 in 2015 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: fell 27.5% in 2015, then skyrocketed 3028.67% in 2016.
  • Crescent Biopharma's Non-Current Deffered Revenue stood at $96756.0 in 2013, then rose by 0.26% to $97012.0 in 2014, then skyrocketed by 151.15% to $243647.0 in 2015, then soared by 209.29% to $753579.0 in 2016, then rose by 6.3% to $801058.0 in 2017.
  • Per Business Quant, the three most recent readings for CBIO's Non-Current Deffered Revenue are $801058.0 (Q3 2017), $813182.0 (Q2 2017), and $754055.0 (Q1 2017).